Page 20 - 中国全科医学2022-29

http://www.chinagp.net E-mail:zgqkyx@chinagp.net.cn ·3601·

Investigator，Nurse，Carer Questionnaire （PINC-Q）： for the management of schizophrenia and related disorders［J］.
a cross-sectional，retrospective，non-interventional study Aust N Z J Psychiatry，2016，50（5）：410-472. DOI：
exploring the impact of less frequent medication administration 10.1177/0004867416641195.
with paliperidone palmitate 3-monthly as maintenance treatment ［60］HASAN A，FALKAI P，WOBROCK T，et al. World Federation
for schizophrenia［J］. BMC Psychiatry，2021，21（1）：300. of Societies of Biological Psychiatry （WFSBP） Guidelines for
DOI：10.1186/s12888-021-03305-z. Biological Treatment of Schizophrenia，part 1：update 2012 on the
［49］LENCER R，GARCIA-PORTILLA M P，BERGMANS P，et al. acute treatment of schizophrenia and the management of treatment
Impact on carer burden when stable patients with schizophrenia resistance［J］. World J Biol Psychiatry，2012，13（5）：318-
transitioned from 1-monthly to 3-monthly paliperidone 378. DOI：10.3109/15622975.2012.696143.
palmitate［J］. Compr Psychiatry，2021，107：152233. DOI： ［61］Japanese Society of Neuropsychopharmacology. Japanese Society of
10.1016/j.comppsych.2021.152233. Neuropsychopharmacology：“guideline for pharmacological therapy
［50］NAJARIAN D，SANGA P N，WANG S，et al. A randomized， of schizophrenia”［J］. Neuropsychopharmacol Rep，2021，41（3）：
double-blind，multicenter，noninferiority study comparing 266-324. DOI：10.1002/npr2.12193.
paliperidone palmitate 6-month versus the 3-month long- ［62］WONG M M C，CHUNG A K K，YEUNG T M H，et al.
acting injectable in patients with schizophrenia［J］. Int J Guidance on the clinical understanding and use of long-acting
Neuropsychopharmacol，2022，25（3）：238-251. DOI： injectable antipsychotics in Schizophrenia：Hong Kong Consensus
10.1093/ijnp/pyab071. Statements［J］. CNS Neurosci Ther，2021，27（Suppl 1）：5-11.
［51］INADA T，INAGAKI A. Psychotropic dose equivalence in DOI：10.1111/cns.13374.
Japan［J］. Psychiatry Clin Neurosci，2015，69（8）：440-447. ［63］YANG K C，LIAO Y T，YANG Y K，et al. Evidence-based
DOI：10.1111/pcn.12275. expert consensus regarding long-acting injectable antipsychotics for
［52］World Health Organization. Management of physical health schizophrenia from the Taiwanese society of biological psychiatry and
conditions in adults with severe mental disorders［R］. Geneva： neuropsychopharmacology （TSBPN）［J］. CNS Drugs，2021，
World Health Organization，2018. 35（8）：893-905. DOI：10.1007/s40263-021-00838-5.
［53］KANE J M，SCHOOLER N R，MARCY P，et al. Patients with ［64］National Institute for Health and Care Excellence. Psychosis and
early-phase schizophrenia will accept treatment with sustained- schizophrenia in adults：prevention and management［M］.
release medication （long-acting injectable antipsychotics）： London：National Institute for Health and Care Excellence （NICE），
results from the recruitment phase of the PRELAPSE trial［J］. 2014.
J Clin Psychiatry，2019，80（3）：18m12546. DOI： ［65］MALLA A，TIBBO P，CHUE P，et al. Long-acting injectable
10.4088/JCP.18m12546. antipsychotics：recommendations for clinicians［J］. Can
［54］LYTLE S，MCVOY M，SAJATOVIC M. Long-acting injectable J Psychiatry，2013，58（5 Suppl 1）：30S-35S. DOI：
antipsychotics in children and adolescents［J］. J Child 10.1177/088740341305805s05.
Adolesc Psychopharmacol，2017，27（1）：2-9. DOI： ［66］SIGN. Management of schizophrenia：a national clinical
10.1089/cap.2016.0055. guideline［M］. Edinburgh：SIGN，2013.
［55］PETRIC D，RACKI V，GACO N，et al. Retrospective analysis ［67］DGPPN e.V. （ed.） for the Guideline Group：S3 Guideline for
of the effectiveness and tolerability of long-acting paliperidone Schizophrenia. Abbreviated version （English），2019，Version 1.0，
palmitate antipsychotic in adolescent first-episode schizophrenia last updated on 29 December 2019［EB/OL］. ［2022-01-20］.
patients［J］. J Child Adolesc Psychopharmacol，2019，29（3）： https://www.awmf.org/leitlinien/detail/ll/038-009.html.
197-204. DOI：10.1089/cap.2018.0044. ［68］LLORCA P M，ABBAR M，COURTET P，et al. Guidelines for
［56］POPE S，ZARAA S G. Efficacy of long-acting injectable the use and management of long-acting injectable antipsychotics in
antipsychotics in adolescents［J］. J Child Adolesc serious mental illness［J］. BMC Psychiatry，2013，13：340.
Psychopharmacol，2016，26（4）：391-394. DOI： DOI：10.1186/1471-244X-13-340.
10.1089/cap.2015.0091. ［69］BARNES T R，DRAKE R，PATON C，et al. Evidence-based
［57］MISAWA F，AMEMIYA A，FUJII Y，et al. Combination therapy guidelines for the pharmacological treatment of schizophrenia：
of long-acting injectable second-generation antipsychotics and oral updated recommendations from the British Association for
antipsychotics：a retrospective chart review and prescribers' attitude Psychopharmacology［J］. J Psychopharmacol，2020，34（1）：
survey［J］. J Clin Psychopharmacol，2022，42（1）：81-86. 3-78. DOI：10.1177/0269881119889296.
DOI：10.1097/JCP.0000000000001487. ［70］HASAN A，FALKAI P，WOBROCK T，et al. World Federation
［58］PAE C U，HAN C S，BAHK W M，et al. Consideration of long- of Societies of Biological Psychiatry （WFSBP） guidelines for
acting injectable antipsychotics for polypharmacy regimen in the biological treatment of schizophrenia，part 2：update 2012 on
treatment of schizophrenia：put it on the table or not? ［J］. Clin the long-term treatment of schizophrenia and management of
Psychopharmacol Neurosci，2021，19（3）：434-448. DOI： antipsychotic-induced side effects［J］. World J Biol Psychiatry，
10.9758/cpn.2021.19.3.434. 2013，14（1）：2-44. DOI：10.3109/15622975.2012.739708.
［59］GALLETLY C，CASTLE D，DARK F，et al. Royal Australian ［71］中华医学会精神医学分会精神分裂症协作组 . 精神分裂
and New Zealand College of Psychiatrists clinical practice guidelines 症患者代谢综合征管理的中国专家共识［J］. 中华精